BIOWA, INC., LICENSES ANTI-FGF8 ANTIBODY FROM KYOWA HAKKO KOGYO CO., LTD.

BioWa announced today that it has successfully licensed from Kyowa Hakko Kogyo Co., Ltd., its parent company, the exclusive worldwide rights except Asia to develop and commercialize Anti-Fibroblast Growth Factor 8 (FGF8) monoclonal antibody, a potential new treatment for breast, ovarian and prostate cancers. Under the terms of the agreement, BioWa expects to develop and commercialize anti-FGF8 antibody, which is currently in pre-clinical development.

Biotech Intelligence (http://www.biotech-intelligence.com/html/html/8e0303f011ebbc8fb2f4fc008e17d852.html)